Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay

To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification. We enrolled all HIV-1-infected patients who initiated tenofovir/emtricitabine...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2014-10, Vol.69 (10), p.2819-2825
Main Authors: Charpentier, Charlotte, Choquet, Marion, Joly, Véronique, Yeni, Patrick, Visseaux, Benoit, Caseris, Marion, Brun-Vézinet, Françoise, Yazdanpanah, Yazdan, Peytavin, Gilles, Descamps, Diane, Landman, Roland
Format: Article
Language:English
Subjects:
Adult
Anti-HIV Agents - pharmacology
Anti-HIV Agents - therapeutic use
Antiretroviral drugs
Bioassays
CD4 Lymphocyte Count
Cross-Sectional Studies
Drug Monitoring
Drug Resistance, Viral - genetics
Female
Genotype
HIV
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - genetics
Human immunodeficiency virus
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Risk Factors
Time Factors
Treatment Outcome
Viral Load
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c351t-436361cc70e5e8f644e88289c7b1b56cecca7fe216667066ce326d0b78102e033
cites cdi_FETCH-LOGICAL-c351t-436361cc70e5e8f644e88289c7b1b56cecca7fe216667066ce326d0b78102e033
container_end_page 2825
container_issue 10
container_start_page 2819
container_title Journal of antimicrobial chemotherapy
container_volume 69
creator Charpentier, Charlotte
Choquet, Marion
Joly, Véronique
Yeni, Patrick
Visseaux, Benoit
Caseris, Marion
Brun-Vézinet, Françoise
Yazdanpanah, Yazdan
Peytavin, Gilles
Descamps, Diane
Landman, Roland
description To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification. We enrolled all HIV-1-infected patients who initiated tenofovir/emtricitabine with efavirenz, darunavir/ritonavir or atazanavir/ritonavir as a first-line regimen between 1 November 2010 and 30 June 2012. An ultrasensitive viral load (VL) assay was performed and plasma drug concentrations at 24 h (C24) were determined at Week (W) 4, W12, W24, W36 and W48. Sixty patients initiated efavirenz, 81 darunavir/ritonavir and 27 atazanavir/ritonavir. A higher proportion of patients with a VL >100 000 copies/mL received darunavir/ritonavir (P = 0.022). At W48, 89%, 85% and 88% of the patients had a VL
doi_str_mv 10.1093/jac/dku211
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1562662025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1562662025</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-436361cc70e5e8f644e88289c7b1b56cecca7fe216667066ce326d0b78102e033</originalsourceid><addsrcrecordid>eNpdkU1rGzEQhkVJqJ20l_6AIMilBDYZfe76WEyaBAy5tL0usnbWlaNdudLKJYf898o4yaGnYd55eBl4CPnC4JrBQtxsjb3pnjJn7AOZM6mh4rBgJ2QOAlRVSyVm5CylLQBopZuPZMblQjY1qDl5-eVi8GHjrPE05MmGAamZ6F_EJyobGno6_Y6INGI5DTh22NHexTRV3o2HeONKmmhObtzQ7KdoUtnd5PZI9y6WWh9MR83Y0Z03aTC0i3lDTUrm-RM57Y1P-Pl1npOf329_LO-r1ePdw_LbqrJCsamSQgvNrK0BFTa9lhKbhjcLW6_ZWmmL1pq6R8601jXoEgiuO1jXDQOOIMQ5-Xrs3cXwJ2Oa2sEli96bEUNOLVOaa82Bq4Je_oduQ45j-e5ASaZAybpQV0fKxpBSxL7dRTeY-NwyaA9S2iKlPUop8MVrZV4P2L2jbxbEP9wyiQw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1564150547</pqid></control><display><type>article</type><title>Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay</title><source>Oxford Journals Online</source><creator>Charpentier, Charlotte ; Choquet, Marion ; Joly, Véronique ; Yeni, Patrick ; Visseaux, Benoit ; Caseris, Marion ; Brun-Vézinet, Françoise ; Yazdanpanah, Yazdan ; Peytavin, Gilles ; Descamps, Diane ; Landman, Roland</creator><creatorcontrib>Charpentier, Charlotte ; Choquet, Marion ; Joly, Véronique ; Yeni, Patrick ; Visseaux, Benoit ; Caseris, Marion ; Brun-Vézinet, Françoise ; Yazdanpanah, Yazdan ; Peytavin, Gilles ; Descamps, Diane ; Landman, Roland</creatorcontrib><description>To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification. We enrolled all HIV-1-infected patients who initiated tenofovir/emtricitabine with efavirenz, darunavir/ritonavir or atazanavir/ritonavir as a first-line regimen between 1 November 2010 and 30 June 2012. An ultrasensitive viral load (VL) assay was performed and plasma drug concentrations at 24 h (C24) were determined at Week (W) 4, W12, W24, W36 and W48. Sixty patients initiated efavirenz, 81 darunavir/ritonavir and 27 atazanavir/ritonavir. A higher proportion of patients with a VL &gt;100 000 copies/mL received darunavir/ritonavir (P = 0.022). At W48, 89%, 85% and 88% of the patients had a VL &lt;50 copies/mL, 69%, 73% and 79% had a VL &lt;20 copies/mL and 45%, 48% and 54% had a VL &lt;1 copy/mL using the ultrasensitive assay in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively. Patients with a detectable VL signal at W48 had a higher baseline VL than those with no detectable VL signal (P = 0.0001). A total of 92%, 93% and 91% of the efavirenz, darunavir and atazanavir C24 values were above the respective effective cut-offs. In this observational cohort, the choice of the regimen was related to the physicians' preferences and the patients' characteristics. The proportion of patients reaching VL &lt;1 copy/mL at W48 was similar in the three regimens and was not associated with drug concentrations.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dku211</identifier><identifier>PMID: 24948705</identifier><language>eng</language><publisher>England: Oxford Publishing Limited (England)</publisher><subject>Adult ; Anti-HIV Agents - pharmacology ; Anti-HIV Agents - therapeutic use ; Antiretroviral drugs ; Bioassays ; CD4 Lymphocyte Count ; Cross-Sectional Studies ; Drug Monitoring ; Drug Resistance, Viral - genetics ; Female ; Genotype ; HIV ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Infections - virology ; HIV-1 - drug effects ; HIV-1 - genetics ; Human immunodeficiency virus ; Humans ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Risk Factors ; Time Factors ; Treatment Outcome ; Viral Load ; Virology</subject><ispartof>Journal of antimicrobial chemotherapy, 2014-10, Vol.69 (10), p.2819-2825</ispartof><rights>The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</rights><rights>Copyright Oxford Publishing Limited(England) Oct 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c351t-436361cc70e5e8f644e88289c7b1b56cecca7fe216667066ce326d0b78102e033</citedby><cites>FETCH-LOGICAL-c351t-436361cc70e5e8f644e88289c7b1b56cecca7fe216667066ce326d0b78102e033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24948705$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Charpentier, Charlotte</creatorcontrib><creatorcontrib>Choquet, Marion</creatorcontrib><creatorcontrib>Joly, Véronique</creatorcontrib><creatorcontrib>Yeni, Patrick</creatorcontrib><creatorcontrib>Visseaux, Benoit</creatorcontrib><creatorcontrib>Caseris, Marion</creatorcontrib><creatorcontrib>Brun-Vézinet, Françoise</creatorcontrib><creatorcontrib>Yazdanpanah, Yazdan</creatorcontrib><creatorcontrib>Peytavin, Gilles</creatorcontrib><creatorcontrib>Descamps, Diane</creatorcontrib><creatorcontrib>Landman, Roland</creatorcontrib><title>Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification. We enrolled all HIV-1-infected patients who initiated tenofovir/emtricitabine with efavirenz, darunavir/ritonavir or atazanavir/ritonavir as a first-line regimen between 1 November 2010 and 30 June 2012. An ultrasensitive viral load (VL) assay was performed and plasma drug concentrations at 24 h (C24) were determined at Week (W) 4, W12, W24, W36 and W48. Sixty patients initiated efavirenz, 81 darunavir/ritonavir and 27 atazanavir/ritonavir. A higher proportion of patients with a VL &gt;100 000 copies/mL received darunavir/ritonavir (P = 0.022). At W48, 89%, 85% and 88% of the patients had a VL &lt;50 copies/mL, 69%, 73% and 79% had a VL &lt;20 copies/mL and 45%, 48% and 54% had a VL &lt;1 copy/mL using the ultrasensitive assay in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively. Patients with a detectable VL signal at W48 had a higher baseline VL than those with no detectable VL signal (P = 0.0001). A total of 92%, 93% and 91% of the efavirenz, darunavir and atazanavir C24 values were above the respective effective cut-offs. In this observational cohort, the choice of the regimen was related to the physicians' preferences and the patients' characteristics. The proportion of patients reaching VL &lt;1 copy/mL at W48 was similar in the three regimens and was not associated with drug concentrations.</description><subject>Adult</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral drugs</subject><subject>Bioassays</subject><subject>CD4 Lymphocyte Count</subject><subject>Cross-Sectional Studies</subject><subject>Drug Monitoring</subject><subject>Drug Resistance, Viral - genetics</subject><subject>Female</subject><subject>Genotype</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - genetics</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><subject>Virology</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpdkU1rGzEQhkVJqJ20l_6AIMilBDYZfe76WEyaBAy5tL0usnbWlaNdudLKJYf898o4yaGnYd55eBl4CPnC4JrBQtxsjb3pnjJn7AOZM6mh4rBgJ2QOAlRVSyVm5CylLQBopZuPZMblQjY1qDl5-eVi8GHjrPE05MmGAamZ6F_EJyobGno6_Y6INGI5DTh22NHexTRV3o2HeONKmmhObtzQ7KdoUtnd5PZI9y6WWh9MR83Y0Z03aTC0i3lDTUrm-RM57Y1P-Pl1npOf329_LO-r1ePdw_LbqrJCsamSQgvNrK0BFTa9lhKbhjcLW6_ZWmmL1pq6R8601jXoEgiuO1jXDQOOIMQ5-Xrs3cXwJ2Oa2sEli96bEUNOLVOaa82Bq4Je_oduQ45j-e5ASaZAybpQV0fKxpBSxL7dRTeY-NwyaA9S2iKlPUop8MVrZV4P2L2jbxbEP9wyiQw</recordid><startdate>201410</startdate><enddate>201410</enddate><creator>Charpentier, Charlotte</creator><creator>Choquet, Marion</creator><creator>Joly, Véronique</creator><creator>Yeni, Patrick</creator><creator>Visseaux, Benoit</creator><creator>Caseris, Marion</creator><creator>Brun-Vézinet, Françoise</creator><creator>Yazdanpanah, Yazdan</creator><creator>Peytavin, Gilles</creator><creator>Descamps, Diane</creator><creator>Landman, Roland</creator><general>Oxford Publishing Limited (England)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201410</creationdate><title>Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay</title><author>Charpentier, Charlotte ; Choquet, Marion ; Joly, Véronique ; Yeni, Patrick ; Visseaux, Benoit ; Caseris, Marion ; Brun-Vézinet, Françoise ; Yazdanpanah, Yazdan ; Peytavin, Gilles ; Descamps, Diane ; Landman, Roland</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-436361cc70e5e8f644e88289c7b1b56cecca7fe216667066ce326d0b78102e033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral drugs</topic><topic>Bioassays</topic><topic>CD4 Lymphocyte Count</topic><topic>Cross-Sectional Studies</topic><topic>Drug Monitoring</topic><topic>Drug Resistance, Viral - genetics</topic><topic>Female</topic><topic>Genotype</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - genetics</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Charpentier, Charlotte</creatorcontrib><creatorcontrib>Choquet, Marion</creatorcontrib><creatorcontrib>Joly, Véronique</creatorcontrib><creatorcontrib>Yeni, Patrick</creatorcontrib><creatorcontrib>Visseaux, Benoit</creatorcontrib><creatorcontrib>Caseris, Marion</creatorcontrib><creatorcontrib>Brun-Vézinet, Françoise</creatorcontrib><creatorcontrib>Yazdanpanah, Yazdan</creatorcontrib><creatorcontrib>Peytavin, Gilles</creatorcontrib><creatorcontrib>Descamps, Diane</creatorcontrib><creatorcontrib>Landman, Roland</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Charpentier, Charlotte</au><au>Choquet, Marion</au><au>Joly, Véronique</au><au>Yeni, Patrick</au><au>Visseaux, Benoit</au><au>Caseris, Marion</au><au>Brun-Vézinet, Françoise</au><au>Yazdanpanah, Yazdan</au><au>Peytavin, Gilles</au><au>Descamps, Diane</au><au>Landman, Roland</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2014-10</date><risdate>2014</risdate><volume>69</volume><issue>10</issue><spage>2819</spage><epage>2825</epage><pages>2819-2825</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification. We enrolled all HIV-1-infected patients who initiated tenofovir/emtricitabine with efavirenz, darunavir/ritonavir or atazanavir/ritonavir as a first-line regimen between 1 November 2010 and 30 June 2012. An ultrasensitive viral load (VL) assay was performed and plasma drug concentrations at 24 h (C24) were determined at Week (W) 4, W12, W24, W36 and W48. Sixty patients initiated efavirenz, 81 darunavir/ritonavir and 27 atazanavir/ritonavir. A higher proportion of patients with a VL &gt;100 000 copies/mL received darunavir/ritonavir (P = 0.022). At W48, 89%, 85% and 88% of the patients had a VL &lt;50 copies/mL, 69%, 73% and 79% had a VL &lt;20 copies/mL and 45%, 48% and 54% had a VL &lt;1 copy/mL using the ultrasensitive assay in the efavirenz, darunavir/ritonavir and atazanavir/ritonavir groups, respectively. Patients with a detectable VL signal at W48 had a higher baseline VL than those with no detectable VL signal (P = 0.0001). A total of 92%, 93% and 91% of the efavirenz, darunavir and atazanavir C24 values were above the respective effective cut-offs. In this observational cohort, the choice of the regimen was related to the physicians' preferences and the patients' characteristics. The proportion of patients reaching VL &lt;1 copy/mL at W48 was similar in the three regimens and was not associated with drug concentrations.</abstract><cop>England</cop><pub>Oxford Publishing Limited (England)</pub><pmid>24948705</pmid><doi>10.1093/jac/dku211</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 2014-10, Vol.69 (10), p.2819-2825
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_1562662025
source Oxford Journals Online
subjects Adult
Anti-HIV Agents - pharmacology
Anti-HIV Agents - therapeutic use
Antiretroviral drugs
Bioassays
CD4 Lymphocyte Count
Cross-Sectional Studies
Drug Monitoring
Drug Resistance, Viral - genetics
Female
Genotype
HIV
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - virology
HIV-1 - drug effects
HIV-1 - genetics
Human immunodeficiency virus
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Risk Factors
Time Factors
Treatment Outcome
Viral Load
Virology
title Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T13%3A51%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Virological%20outcome%20at%20week%2048%20of%20three%20recommended%20first-line%20regimens%20using%20ultrasensitive%20viral%20load%20and%20plasma%20drug%20assay&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Charpentier,%20Charlotte&rft.date=2014-10&rft.volume=69&rft.issue=10&rft.spage=2819&rft.epage=2825&rft.pages=2819-2825&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dku211&rft_dat=%3Cproquest_cross%3E1562662025%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c351t-436361cc70e5e8f644e88289c7b1b56cecca7fe216667066ce326d0b78102e033%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1564150547&rft_id=info:pmid/24948705&rfr_iscdi=true